Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 9/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7964333 | 0.80 | KMT2A (0.51) | CA2CA9CA12CA1CA4 | |
| SCHEMBL7959381 | 0.77 | KDM4E (0.38) | CA2CA9CA12CA1CA4 | |
| SCHEMBL18061244 | 0.76 | KDM4E (0.46) | CA2CA9CA12CA1CA4 | |
| SCHEMBL22292512 | 0.75 | OPRL1 (0.42) | CA2CA9CA12CA1CA4 | |
| SCHEMBL16285369 | 0.75 | CA12 (0.41) | CA2CA9CA12CA1CA4 | |
| SCHEMBL4484544 | 0.75 | KDM4E (0.63) | CA2CA9CA12CA1CA4 | |
| SCHEMBL17858470 | 0.75 | KDM4E (0.44) | CA2CA9CA12CA1CA4 | |
| SCHEMBL11807174 | 0.75 | KDM4E (0.63) | CA2CA9CA12CA1CA4 | |
| SCHEMBL13292328 | 0.75 | OPRL1 (0.39) | CA2CA9CA12CA1CA4 | |
| SCHEMBL3691840 | 0.73 | GAA (0.50) | CA9CA12KDM4EOPRL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203589-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | InventisBio Co., Ltd. (CN) | 2021-12-21 | — | — | US | disclosed |
| EP-3885344-A2 | PYRIMIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | InventisBio Co., Ltd. (CN) | 2021-09-29 | — | — | EP | disclosed |
| US-20190152969-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | INVENTISBIO SHANGHAI LTD. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-10179784-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | INVENTISBIO SHANGHAI LTD. (CN) | 2019-01-15 | — | — | US | disclosed |
| WO-2018140599-A1 | BENZOTHIOPHENE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018140512-A1 | FUSED BICYCLIC BENZOHETEROAROMATIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018140514-A1 | 1-(6-(3-HYDROXYNAPHTHALEN-1-YL)QUINAZOLIN-2-YL)AZETIDIN-1-YL)PROP-2-EN-1-ONE DERIVATIVES AND SIMILAR COMPOUNDS AS KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018140600-A1 | FUSED HETERO-HETERO BICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018068017-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-04-12 | — | — | WO | disclosed |
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | InventisBio Co., Ltd. (CN) | 2017-12-14 | — | — | US | disclosed |
| EP-3216786-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | Shanghai Shaletech Technology Co., Ltd. (CN) | 2017-09-13 | — | — | EP | disclosed |
| US-7601744-B2 | Benzothiadiazolylphenylalkylamine derivatives and methods of their use | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1934193-A1 | BENZOTHIADIAZOLYPHENYLALKYLAMINE DERIVATIVES FOR USE IN THE TREATMENT OF CONDITIONS AMELIORATED BY MONOAMINE REUPTAKE | Wyeth a Corporation of the State of Delaware (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007041258-A1 | BENZOTHIADIAZOLYPHENYLALKYLAMINE DERIVATIVES FOR USE IN THE TREATMENT OF CONDITIONS AMELIORATED BY MONOAMINE REUPTAKE | WYETH (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072918-A1 | Benzothiadiazolylphenylalkylamine derivatives and methods of their use | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
| US-6774134-B2 | FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |
| US-6774134-B2 | FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152969-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | EGFR, WEE1, DPYD | CA2 3821/4885CA9 2367/4885CA12 4628/4885 |
| US-11203589-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | EGFR, WEE1, TP53 | CA2 4305/4885CA9 2789/4885CA12 4770/4885 |
| US-20070072918-A1 | Benzothiadiazolylphenylalkylamine derivatives and methods of their use | GLS, SLC6A4, SLC6A3 | CA2 2800/4885CA9 4163/4885CA12 4567/4885 |
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | EGFR, WEE1, DPYD | CA2 3896/4885CA9 1908/4885CA12 4570/4885 |
| US-10179784-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | EGFR, WEE1, DPYD | CA2 3821/4885CA9 2367/4885CA12 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.